Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albizia julibrissin leaf extract (AJLE) is a botanical extract derived from the leaves of the silk tree, currently being investigated for its anti-cancer properties, particularly in pancreatic cancer. Prepared as a hot water extract, AJLE has demonstrated the ability to inhibit cell proliferation and induce apoptosis in pancreatic cancer cells. Its mechanism of action involves the disruption of oncogenic signaling pathways, specifically the suppression of MAPK and PI3K/AKT pathways, while simultaneously upregulating EGFR expression to trigger EGFR-mediated apoptosis. Preclinical studies in xenograft mouse models have shown dose-dependent tumor growth reduction without significant systemic toxicity to the liver or kidneys.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albizia julibrissin leaf extract.